Song Zhengbo, Yu Xinmin, Lou Guangyuan, Shi Xun, Zhang Yiping
Department of Chemotherapy, Zhejiang Cancer Hospital; Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Zhejiang province, Hangzhou, People's Republic of China.
Onco Targets Ther. 2017 Mar 23;10:1821-1825. doi: 10.2147/OTT.S113435. eCollection 2017.
No definitive chemotherapeutic regimen has been established in patients with non-small-cell lung cancer (NSCLC) who failed second- or third-line treatment. The aim of this study was to evaluate apatinib, a VEGFR-2 inhibitor, in advanced NSCLC as salvage treatment.
We evaluated the efficacy and toxicity of apatinib in patients with previously treated advanced NSCLC from 2014 to 2015 in Zhejiang Cancer Hospital. Survival analysis was performed by the Kaplan-Meier method.
Forty-two patients were included in the present study. Four patients achieved partial response, and 22 achieved stable disease, representing a response rate of 9.5% and a disease control rate of 61.9%. Median progression-free survival and overall survival were 4.2 and 6.0 months, respectively. The toxicities associated with apatinib were generally acceptable with a total grade 3/4 toxicity of 50%.
Apatinib appears to have some activity against advanced NSCLC when utilized as salvage treatment.
对于接受二线或三线治疗失败的非小细胞肺癌（NSCLC）患者，尚未确立明确的化疗方案。本研究旨在评估血管内皮生长因子受体-2（VEGFR-2）抑制剂阿帕替尼在晚期NSCLC挽救治疗中的作用。
2014年至2015年期间，我们在浙江省肿瘤医院评估了阿帕替尼对既往接受过治疗的晚期NSCLC患者的疗效和毒性。采用Kaplan-Meier法进行生存分析。
本研究共纳入42例患者。4例患者达到部分缓解，22例患者病情稳定，缓解率为9.5%，疾病控制率为61.9%。无进展生存期和总生存期的中位数分别为4.2个月和6.0个月。阿帕替尼相关毒性总体可接受，3/4级毒性总发生率为50%。
阿帕替尼作为挽救治疗用于晚期NSCLC时似乎具有一定活性。
